RecruitingPhase 2NCT05799521
A Nasal Treatment for COVID-19
A Novel Nasal Treatment for COVID-19
Sponsor
Indiana University
Enrollment
40 participants
Start Date
Jun 27, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this study is to test an investigational new inhaled medication called Optate.
Eligibility
Min Age: 18 YearsMax Age: 60 Years
Inclusion Criteria6
- positive rapid COVID-19 test
- Ordinal Scale for Clinical Improvement < 3 (OSCI, Appendix 2) and/or
- Fever > 100 degree F and/or
- Nasal congestion
- negative rapid COVID-19 test
- No known medical problems or taking any medication that, in the investigator's opinion, would make them unsuitable for participation.
Exclusion Criteria6
- FEV1 (Forced Exhaled Volume) < 55% predicted on the day of study procedures
- OSCI ≥ 3 (Objective Structured Clinical Exam)
- Pregnancy
- Inability to follow commands or perform study procedures including spirometry, coordinated inhalation of study medication
- Pregnancy
- Inability to follow commands or perform study procedures including spirometry, coordinated inhalation of study medication
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGOptate
Alkaline Buffer
DRUGPlacebo
Normal Saline
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05799521
Related Trials
Study of New Magnetic Resonance Imaging Methods of the Brain
NCT000045771 location
A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
NCT072211628 locations
Predicting Future Errors During Skill Performance
NCT067072071 location
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
NCT071696301 location
Validation of Energy Expenditure Measures Study
NCT071555641 location